0001411690 2026-10-27 2026-10-27 0001411690 1 2026-10-27 2026-10-27 0001411690 2 2026-10-27 2026-10-27 0001411690 3 2026-10-27 2026-10-27 0001411690 4 2026-10-27 2026-10-27 0001411690 1 2026-10-27 2026-10-27 0001411690 2 2026-10-27 2026-10-27 iso4217:USD pure shares S-1 S-1 EX-FILING FEES 0001411690 Bionano Genomics, Inc. N/A true false S-1 Bionano Genomics, Inc. false Equity Common Stock, par value $0.0001 per share true 661377 15.12 10000020.24 0.000087 870.00 false Equity Common Stock, par value $0.0001 per share true 164684 18.234 3002848.06 0.000087 261.25 false Equity Common Stock, par value $0.0001 per share true 145560 61.20 8908272.00 0.000087 775.02 false Equity Common Stock, par value $0.0001 per share true 361011 191.13 69000032.43 0.000087 6003.00 90911172.73 7909.27 0.00 7909.27 0.00 (1) Represents 661,377 shares of common stock issuable upon exercise of outstanding 2025 Purchase Warrants, which were originally issued under the Registrant's registration statement on Form S-3 (File No. 333-270459), initially declared effective on May 10, 2023 (the "Prior Registration Statement"). Calculated pursuant to Rule 457(g) under the Securities Act of 1933, as amended (the "Securities Act"), the proposed maximum offering price per unit and maximum aggregate offering price are based on the per share exercise price of the 2025 Purchase Warrants and are presented for informational purposes only. Pursuant to Rule 416 under the Securities Act, this registration statement also covers an indeterminate number of additional shares of common stock that may become issuable upon exercise of the 2025 Purchase Warrants to prevent dilution resulting from stock splits, stock dividends or similar transactions. (2) Represents 164,684 shares of common stock issuable upon exercise of outstanding Series C Warrants, which were originally issued under the Registrant's Prior Registration Statement. Calculated pursuant to Rule 457(g) under the Securities Act, the proposed maximum offering price per unit and maximum aggregate offering price are based on the per share exercise price of the Series C Warrants and are presented for informational purposes only. Pursuant to Rule 416 under the Securities Act, this registration statement also covers an indeterminate number of additional shares of common stock that may become issuable upon exercise of the Series C Warrants to prevent dilution resulting from stock splits, stock dividends or similar transactions. (3) Represents 145,560 shares of common stock issuable upon exercise of outstanding 2024 Purchase Warrants, which were originally issued under the Registrant's Prior Registration Statement. Calculated pursuant to Rule 457(g) under the Securities Act, the proposed maximum offering price per unit and maximum aggregate offering price are based on the per share exercise price of the 2024 Purchase Warrants and are presented for informational purposes only. Pursuant to Rule 416 under the Securities Act, this registration statement also covers an indeterminate number of additional shares of common stock that may become issuable upon exercise of the 2024 Purchase Warrants to prevent dilution resulting from stock splits, stock dividends or similar transactions. (4) Represents 361,011 shares of common stock issuable upon exercise of outstanding 2023 Purchase Warrants, which were originally issued under the Registrant's Prior Registration Statement. Calculated pursuant to Rule 457(g) under the Securities Act, the proposed maximum offering price per unit and maximum aggregate offering price are based on the per share exercise price of the 2023 Purchase Warrants and are presented for informational purposes only. Pursuant to Rule 416 under the Securities Act, this registration statement also covers an indeterminate number of additional shares of common stock that may become issuable upon exercise of the 2023 Purchase Warrants to prevent dilution resulting from stock splits, stock dividends or similar transactions. true Bionano Genomics, Inc. S-3 333-270459 2023-03-10 7909.27 Unallocated (Universal) Shelf Unallocated (Universal) Shelf 90911169.42 true Bionano Genomics, Inc. S-3 333-270459 2023-03-10 10018.41 (5) Pursuant to Rule 457(p) under the Securities Act, the Registrant is offsetting the total registration fee of $7,909.27 due under this registration statement against the filing fee previously paid in connection with unsold securities registered under the Prior Registration Statement, which was initially filed on March 10, 2023. The unsold securities associated with the fee offset claimed consist of an aggregate of 1,332,628 shares of common stock issuable upon exercise of the 2025 Purchase Warrants, the Series C Warrants, the 2024 Purchase Warrants and the 2023 Purchase Warrants, which remain outstanding and have not been exercised. Such unsold securities have an unsold aggregate offering amount of $90,911,169.42, and the Registrant paid a filing fee of $10,018.41 in connection with the unsold securities associated with the fee offset claimed, calculated at the fee rate in effect at the time of the filing of the Prior Registration Statement. Of that amount, $7,909.27 is being used to offset the registration fee due under this registration statement, and the remaining $2,109.14 is not being applied hereto. As a result, no filing fee is due with this registration statement. The offering of the securities associated with the fee offset claimed herein has been terminated or completed, and such securities remain unsold.